Navigation Links
FDA Indicates That Genasense(R) Approval in Chronic Lymphocytic Leukemia Will Require Additional Confirmatory Data
Date:3/17/2008

ed as "non-refractory" (N=101), who are the focus of the proposed trial, the CR rate was 25% (13 of 51) in the Genasense group compared with 6% (3 of 50) in the Flu/Cy-only group (P=0.016). Extended followup has also demonstrated superior survival for patients who achieved CR in the Genasense group.

A scientific report of the safety and efficacy findings from the preceding study was published in the Journal of Clinical Oncology (25:1114, 2007).

Conference Call

Genta management will further discuss the current status and forward strategy for Genasense in CLL in a conference call and webcast on Tuesday March 18, 2008 at 8:30 AM EDT. Participants can access the live call by dialing (877) 634-8606 (U.S. and Canada) or (706) 679-3140 (International). The access code for the live call is Genta Incorporated, conference ID number 39856497. The call will also be webcast live at http://www.genta.com/investorrelation/events.html.

For investors unable to participate in the live call, a replay will be available approximately two hours after completion of the call, and will be archived for 30 days. Access numbers for this replay are: (800) 642-1687 (U.S. and Canada) and (706) 645-9291 (International); conference ID number is: 39856497.

About Chronic Lymphocytic Leukemia

CLL is the most common form of leukemia in adults. According to the American Cancer Society, approximately 8,000 patients will be diagnosed this year. More than 60,000 people in the U.S. currently have CLL. The disease arises in lymphocytes, a type of white blood cell that normally produces antibodies and serves important immune functions. Patients with CLL typically develop symptoms that may progress over a period of years, ultimately producing a generalized depression of immunity, marked increases in the size of spleen, liver and lymph nodes, and impaired production of other normal blood cells.
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. FDA Extends Review of Genasense(R) NDA Appeal in Chronic Lymphocytic Leukemia
2. FDA to Extend Review of Data Quality Submission for Genasense(R) in Melanoma
3. Genasense(R) Data in Patients with Advanced Melanoma to be Featured at 4th International Melanoma Congress
4. Genasense(R) Can be Administered by Brief High-Dose IV Infusion
5. Authorization for AGENDA Phase 3 Trial of Genasense(R) in Advanced Melanoma Granted by French Regulatory Agency
6. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
7. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
8. FDA Advisory Committee Unanimously Recommends U.S. Approval of Sugammadex, the First and Only Selective Relaxant Binding Agent
9. CSL Behring Submits BLA Requesting Approval of C1-Esterase Inhibitor for the Treatment of Hereditary Angioedema
10. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
11. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) ... Officer, will be presenting at the 26 th Annual ... in New York . The formal presentation ... ET. In addition, Mr. Krakauer and Jorgen B. Hansen ... meetings during the day. An audio webcast ...
(Date:11/21/2014)... Depomed, Inc. (NASDAQ: DEPO ) today announced that it ... Healthcare Conference in New York City . ... 8:00 am EST (5:00 am PST) on Tuesday December 2, 2014.  ... via the Investor Relations page of the Depomed website at ... 30 days on the company,s website. About Depomed ...
(Date:11/21/2014)... 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... of $80,000,000 aggregate principal amount of 5.25% Convertible Senior ... offering within the United States . ... pursuant to Rule 144A under the Securities Act of ... granted the initial purchasers an option to purchase up ...
Breaking Medicine Technology:Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3
... Therapy Trial planned for 2008, TARRYTOWN, N.Y., ... Exchange: EPCT) today announced that it has,completed its ... has met all of,its objectives. EPC2407 is EpiCept,s ... inducer for the treatment of patients,with advanced solid ...
... Oct. 5 Boehringer Ingelheim,Pharmaceuticals, Inc. today ... (FDA) granted full (traditional) approval of Aptivus(R),(tipranavir) ... APTIVUS in,June 2005; accelerated approval is a ... for serious or life-threatening illnesses. The full,approval ...
Cached Medicine Technology:EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407 2EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407 3EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407 4EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407 5EpiCept Announces Successful Completion of Enrollment for Phase I Trial of EPC2407 6Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 2Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 3Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 4Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 5Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 6Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 7Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA 8
(Date:11/22/2014)... 22, 2014 “Due to my knee replacement ... from Gurnee, Ill. “While using the ice grip attachment, I ... thought there needed to be a safer way to prevent ... BLOCK. , The SPIKE BLOCK offers added safety and stability ... help to reduce injuries and damage associated with traditional spiked ...
(Date:11/22/2014)... order to provide better services, LunaDress has updated its website ... knows that a suitable cocktail party dress is crucial for ... party dresses supplier’s high quality items are offered at attracting ... fashion industry, LunaDress understands that it is not easy to ... raises the professional level and innovation ability. The growth of ...
(Date:11/22/2014)... "My friend went in for a mammogram ... said an inventor from Cambria Heights, N.Y. "To add ... second time because the first results were inaccurate. Her ... patent-pending MAMO EASY to offer a more comfortable way ... patient from the pain normally involved with this procedure. ...
(Date:11/22/2014)... Domestic farmgate milk and dairy solids ... to a fall in demand for Butter ... the global financial crisis. However, these declines did ... manufacturers on the international scene. Strong growth in ... primarily due to supply constraints in some key ...
(Date:11/22/2014)... November 22, 2014 The topic of ... of block retaining walls. The article states that, “While they ... several necessary steps that go into creating this powerful look.” ... a retaining wall is choosing which kind of block matches ... , B&D Rockeries says, “The two main options are concrete ...
Breaking Medicine News(10 mins):Health News:LunaDress Unveils Fabulous Cocktail Party Dresses 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 2Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 3Health News:Butter and Dairy Product Manufacturing in Australia Industry Market Research Report Now Updated by IBISWorld 4Health News:5 Step Installment of Block Retaining Walls is Topic of Latest Article by B&D Rockeries 2
... had a ,protective, effect , , TUESDAY, Oct. 30 (HealthDay ... depression finds that their risk factors for suicide differ ... , Specifically, the risk for suicide appears highest among ... the general population. , And even though post-traumatic stress ...
... Roper Industries,Inc. (NYSE: ROP ) announced that ... on Tuesday, November 6, 2007 at 1:20 PM (Central,Time), ... of the presentation,will be available in the "Investor Information" ... About Roper Industries Roper Industries is a market-driven, ...
... Calif., Oct. 30 West Anaheim Medical,Center, ... (PHS), has,installed a state-of-the-art patient tracking and ... within the hospital,s MEDITECH,system, the application is ... assist providers in managing their Emergency Department,patients ...
... knowledge of basic vision care, safety, survey finds , , ... half of all American adults say eyesight is their ... says an American Optometric Association (AOA) survey released Monday. ... years or older found that Americans lack awareness in ...
... Wellness Destination, The HealthCentral,Network, Recognized by the ... ARLINGTON, Va., Oct. 30 The ... from the,International Academy of the Visual Arts ... The W3 Awards, which honors creative,excellence on ...
... Oct 30 Perrigo Company,(Nasdaq: PRGO ; TASE) ... dividend of $0.05 per share, payable on December 18, ... new quarterly dividend of,$0.05 per share represents an eleven ... four quarters. Perrigo Company is a leading global ...
Cached Medicine News:Health News:Younger Veterans at Greater Suicide Risk 2Health News:Younger Veterans at Greater Suicide Risk 3Health News:Younger Veterans at Greater Suicide Risk 4Health News:Hospital Launches State-of-the-Art Patient Tracking and Integrated Patient Data System 2Health News:Most Americans Have Poor 'Eye-Q' 2Health News:The HealthCentral Network Wins W3 Award for Breast Cancer Web Site 2
PoleStar N-10 is a compact MRI unit that does not require a specially constructed surgery suite. The magnetic field is confined to the volume between the magnet poles and it's immediate neighborhood....
... Surgical Adhesive (Bioglue) is a two-component ... serum albumin (BSA) and glutaraldehyde. The ... from bovine spongiform encephalopathy (BSE) free ... or inactivates viruses. The solutions are ...
Avitene Microfibrillar Collagen (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
Exclusive oxidized regenerated cellulose technology. The only oxidized regenerated cellulose hemostat line, surgicel absorbable hemostat delivers a unique combination of effectiveness, absorbability,...
Medicine Products: